Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Oncology market: From $286B to $581B (2030)
View:
Post by ScienceFirst on May 08, 2023 11:37am

Oncology market: From $286B to $581B (2030)

According to a report by Precedence Research, the oncology market is expected to grow from $286 billion in 2021 to over $581 billion by 2030, a compound annual growth rate of 8.2%.
Comment by 99942Apophis on May 08, 2023 1:33pm
Interesting statistic ScienceFirst however those figures have been calculated on current treatments, Theralase's treatment as we are much less costly thereby greatly reducing the expense to individuals and insurance companies. There are so many pluses with Theralase's treatment that when it does get media attention this company will become the main sensation in my not so humble opinion ...more  
Comment by BlueFranky on May 08, 2023 2:15pm
Thanks for your post as always, Apophis, I was drawn back to a post you made in March:  RE:Pfizer buys Seagen for 43B$ .... Where you commented as follows: "I think many of TLT shareholders had eyes on this one, Pfizer looks like a giant roller in action. My guess is if BTD does come through with an improved CR then it will be down to both Merck and Pfizer fighting it ...more  
Comment by ScienceFirst on May 08, 2023 3:26pm
BlueFranky ... I think Roche, the 3rd largest pharma in the world, can be a serious jv candidate.  They've been targeting urology with focus on bladder and prostate. Nov. 2022, they withdrew from the bladder indication in the US after failing it confirmatory trial that came with the 2016 Accelerated Approval. And last week, they failed in a prostate trial.   So maybe they ...more  
Comment by 99942Apophis on May 08, 2023 3:32pm
Hi BlueFranky,  difficult to say Pfizer is loaded with cash but Merck needs Theralase's treatment,  who knows eh, we might see blood in the streets with this one.  Too many variables to change any of my previous hypothetical future share price range of $19.50 to $112.00   Lets just sit on this range until we actually hear something. 
Comment by BlueFranky on May 08, 2023 5:00pm
Thanks Apophis and thank you as well Sciencefirst I am optimistic that they are all paying close attention not only to our recent data but also the trajectory that we seem to be heading in with each new set of numbers and the possible chokehold on SOC Here's hoping that one if not all of them are thinking of a preemptive strike, be it a JV or more. Apophis I like your range, especially the ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250